Edition:
United States

Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

3.65USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
87,860
52-wk High
$5.50
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

Cascadian Therapeutics reports Q3 loss per share $0.28
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Cascadian Therapeutics Inc ::Cascadian Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.28.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Cascadian therapeutics - ‍ cash, cash equivalents and investments totaled $113.0 million as of Sept 30, 2017, compared to $62.8 million at Dec 31, 2016​.Cascadian Therapeutics Inc - ‍ cash used in operations for 2017 is expected to be approximately $50.0 million to $54.0 million​.  Full Article

Cascadian Therapeutics announces FDA orphan drug designation granted to Tucatinib for the treatment of HER2 colorectal cancer
Wednesday, 27 Sep 2017 07:00am EDT 

Sept 27 (Reuters) - Cascadian Therapeutics Inc ::Cascadian Therapeutics announces FDA orphan drug designation granted to tucatinib for the treatment of HER2+ metastatic colorectal cancer.  Full Article

Cascadian Therapeutics Q2 loss per share $0.30
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Cascadian Therapeutics Inc :Cascadian Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.30.Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Cascadian Therapeutics Inc - ‍expects operating expenses in 2017 to be slightly higher than in 2016​.Cascadian Therapeutics Inc - ‍cash used in operations for 2017 is expected to be approximately $50.0 million to $54.0 million​.  Full Article

Cascadian Therapeutics announces positive regulatory update for Tucatinib in Europe
Tuesday, 11 Jul 2017 08:00am EDT 

July 11 (Reuters) - Cascadian Therapeutics Inc :Cascadian Therapeutics announces positive regulatory update for tucatinib in Europe.Cascadian Therapeutics Inc - ‍announced outcome of discussions with European Medicines Agency (EMA) regarding development of tucatinib​.Cascadian Therapeutics - received confirmation that positive results from her2climb could serve as single registrational trial for submission of MAA to EMA, potential marketing approval​.Cascadian Therapeutics - ‍site, patient enrollment currently ahead of schedule in n. America, Poised to begin enrolling patients in her2climb in other countries​.  Full Article

Cascadian Therapeutics’ tucatinib, receives orphan drug designation from FDA
Thursday, 8 Jun 2017 08:00am EDT 

June 8 (Reuters) - Cascadian Therapeutics Inc :Cascadian therapeutics' lead candidate, tucatinib, receives orphan drug designation from fda for treatment of breast cancer patients with brain metastases‍​.  Full Article

BRIEF-Cascadian says stockholder Growth Equity Opportunities Fund IV has option to resell 1.82 mln of co's shares (May 8)
Wednesday, 10 May 2017 10:57am EDT 

Corrects May 8 brief headline to say company's stockholder Growth Equity Opportunities Fund IV, not Cascadian, may resell up to 1.82 million shares. Adds bullets with additional details of financing:Files S-3 related to possible resale of up to 1.82 million shares of common stock by Growth Equity Opportunities Fund IV and its affiliates - SEC filing.Growth Equity Opportunities Fund IV has option to resell common shares of the company, as part of Series E preferred stock financing announced in January by Cascadian ID:nGNXNOBHMa.S-3 filing is not related to a new secondary issue by Cascadian .Cascadian will not receive any cash proceeds from the possible sale of any of shares of common stock by Growth Equity Opportunities Fund .  Full Article

Cascadian Therapeutics reports Q1 loss per share of $0.30
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Cascadian Therapeutics Inc :Q1 loss per share $0.30.Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Expects operating expenses in 2017 to be slightly higher than in 2016, due to rise in activities related to her2climb pivotal trial.Cash used in operations for 2017 is expected to be approximately $50.0 million to $54.0 million.  Full Article

Cascadian Therapeutics Q4 loss per share $0.47
Thursday, 9 Mar 2017 04:01pm EST 

Cascadian Therapeutics Inc : Cascadian Therapeutics reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.47 .Q4 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

Cascadian Therapeutics received a notice from BVF Partners L.P. and others terminating letter agreement
Friday, 3 Feb 2017 05:12pm EST 

Cascadian Therapeutics Inc :Cascadian Therapeutics Inc- On February 2, 2017, company received a notice from BVF Partners L.P. and others terminating letter agreement.  Full Article

Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib in metastatic HER2-positive breast cancer to support registration
Wednesday, 7 Dec 2016 07:00am EST 

Cascadian Therapeutics Inc : Cascadian Therapeutics Inc - updated data from phase 1b triplet combination trial at sabcs . Cascadian Therapeutics Inc - her2climb amended to single pivotal randomized trial to assess progression-free survival (pfs) as primary endpoint . Cascadian Therapeutics Inc- HER2CLIMB is currently enrolling in United States and Canada and is expected to expand into Europe, Australia and Israel . Cascadian Therapeutics - after meeting with FDA, amended HER2CLIMB phase 2 clinical trial of tucatinib by increasing sample size . Updated phase 1b trial results for triplet combination show that combination continues to be well tolerated .Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib in metastatic her2-positive breast cancer to support registration.  Full Article